195 related articles for article (PubMed ID: 35115509)
1. The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression.
Guo Y; Zhu H; Xiao Y; Guo H; Lin M; Yuan Z; Yang X; Huang Y; Zhang Q; Bai Y
Cell Death Dis; 2022 Feb; 13(2):112. PubMed ID: 35115509
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-Myc signaling pathway by inducing β-catenin ubiquitination in pancreatic cancer.
Kang HW; Kim JH; Lee DE; Lee YS; Kim MJ; Kim HS; Fang S; Lee BE; Lee KJ; Yoo J; Kim HJ; Park JS
Cancer Biol Ther; 2023 Dec; 24(1):2272334. PubMed ID: 37917550
[TBL] [Abstract][Full Text] [Related]
3. The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC.
Wang LH; Xu M; Fu LQ; Chen XY; Yang F
Sci Rep; 2018 Aug; 8(1):12776. PubMed ID: 30143678
[TBL] [Abstract][Full Text] [Related]
4. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
Lu W; Lin C; Roberts MJ; Waud WR; Piazza GA; Li Y
PLoS One; 2011; 6(12):e29290. PubMed ID: 22195040
[TBL] [Abstract][Full Text] [Related]
5. Correction: The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression.
Guo Y; Zhu H; Xiao Y; Guo H; Lin M; Yuan Z; Yang X; Huang Y; Zhang Q; Bai Y
Cell Death Dis; 2022 Apr; 13(4):366. PubMed ID: 35440080
[No Abstract] [Full Text] [Related]
6. Targeting Wnt/β-catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer.
Wei W; Liu H; Yuan J; Yao Y
Fundam Clin Pharmacol; 2021 Feb; 35(1):165-173. PubMed ID: 32579788
[TBL] [Abstract][Full Text] [Related]
7. The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine.
Jung DB; Yun M; Kim EO; Kim J; Kim B; Jung JH; Wang E; Mukhopadhyay D; Hammond E; Dredge K; Shridhar V; Kim SH
Oncotarget; 2015 Mar; 6(7):4992-5004. PubMed ID: 25669977
[TBL] [Abstract][Full Text] [Related]
8. DKK3 blocked translocation of β-catenin/EMT induced by hypoxia and improved gemcitabine therapeutic effect in pancreatic cancer Bxpc-3 cell.
Guo Q; Qin W
J Cell Mol Med; 2015 Dec; 19(12):2832-41. PubMed ID: 26395974
[TBL] [Abstract][Full Text] [Related]
9. FAT4 overexpression promotes antitumor immunity by regulating the β-catenin/STT3/PD-L1 axis in cervical cancer.
Wang D; Wu S; He J; Sun L; Zhu H; Zhang Y; Liu S; Duan X; Wang Y; Xu T
J Exp Clin Cancer Res; 2023 Sep; 42(1):222. PubMed ID: 37658376
[TBL] [Abstract][Full Text] [Related]
10. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma
Zhou J; Jin B; Jin Y; Liu Y; Pan J
Theranostics; 2017; 7(6):1447-1462. PubMed ID: 28529629
[TBL] [Abstract][Full Text] [Related]
11. Rab11a sustains GSK3β/Wnt/β-catenin signaling to enhance cancer progression in pancreatic cancer.
Yu L; Li X; Li H; Chen H; Liu H
Tumour Biol; 2016 Oct; 37(10):13821-13829. PubMed ID: 27481517
[TBL] [Abstract][Full Text] [Related]
12. Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.
Wang J; Mook RA; Ren XR; Zhang Q; Jing G; Lu M; Spasojevic I; Lyerly HK; Hsu D; Chen W
Bioorg Med Chem; 2018 Nov; 26(20):5435-5442. PubMed ID: 30274939
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of β-catenin signaling suppresses pancreatic tumor growth by disrupting nuclear β-catenin/TCF-1 complex: critical role of STAT-3.
Pramanik KC; Fofaria NM; Gupta P; Ranjan A; Kim SH; Srivastava SK
Oncotarget; 2015 May; 6(13):11561-74. PubMed ID: 25869100
[TBL] [Abstract][Full Text] [Related]
14. Suppression of Wnt/β-catenin and RAS/ERK pathways provides a therapeutic strategy for gemcitabine-resistant pancreatic cancer.
Ryu WJ; Han G; Lee SH; Choi KY
Biochem Biophys Res Commun; 2021 Apr; 549():40-46. PubMed ID: 33662667
[TBL] [Abstract][Full Text] [Related]
15. Wogonoside Inhibits Prostate Cancer Cell Growth and Metastasis via Regulating Wnt/β-Catenin Pathway and Epithelial-Mesenchymal Transition.
Wei C; Jing J; Zhang Y; Fang L
Pharmacology; 2019; 104(5-6):312-319. PubMed ID: 31480051
[TBL] [Abstract][Full Text] [Related]
16. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
[TBL] [Abstract][Full Text] [Related]
17. Silencing of lemur tyrosine kinase 2 restricts the proliferation and invasion of hepatocellular carcinoma through modulation of GSK-3β/Wnt/β-catenin signaling.
Zhao G; Song Y; Dong L; Shi H; Li H; Yang L; Wang J
Biochem Biophys Res Commun; 2019 Oct; 517(4):722-728. PubMed ID: 31395338
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-300 promotes apoptosis and inhibits proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway by targeting CUL4B in pancreatic cancer cells.
Zhang JQ; Chen S; Gu JN; Zhu Y; Zhan Q; Cheng DF; Chen H; Deng XX; Shen BY; Peng CH
J Cell Biochem; 2018 Jan; 119(1):1027-1040. PubMed ID: 28685847
[TBL] [Abstract][Full Text] [Related]
19. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H
Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012
[TBL] [Abstract][Full Text] [Related]
20. WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer.
King ML; Lindberg ME; Stodden GR; Okuda H; Ebers SD; Johnson A; Montag A; Lengyel E; MacLean Ii JA; Hayashi K
Oncogene; 2015 Jun; 34(26):3452-62. PubMed ID: 25174399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
